Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/337533
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.author | Mensali, Nadia | es_ES |
dc.contributor.author | Köksal, Hakan | es_ES |
dc.contributor.author | Joaquina, Sandy | es_ES |
dc.contributor.author | Wernhoff, Patrik | es_ES |
dc.contributor.author | Casey, Nicholas P. | es_ES |
dc.contributor.author | Romecin, Paola | es_ES |
dc.contributor.author | Panisello, Carla | es_ES |
dc.contributor.author | Rodriguez, René | es_ES |
dc.contributor.author | Vimeux, Lene | es_ES |
dc.contributor.author | Juzeniene, Asta | es_ES |
dc.contributor.author | Myhre, Marit R. | es_ES |
dc.contributor.author | Fåne, Anne | es_ES |
dc.contributor.author | Castilla, Carolina | es_ES |
dc.contributor.author | Maggadottir, Solrun Melkorka | es_ES |
dc.contributor.author | Duru, Adil Doganay | es_ES |
dc.contributor.author | Georgoudaki, Anna-Maria | es_ES |
dc.contributor.author | Grad, Iwona | es_ES |
dc.contributor.author | Maturana, Andrés Daniel | es_ES |
dc.contributor.author | Gaudernack, Gustav | es_ES |
dc.contributor.author | Kvalheim, Gunnar | es_ES |
dc.contributor.author | Carcaboso, Ángel M. | es_ES |
dc.contributor.author | Álava, Enrique de | es_ES |
dc.contributor.author | Donnadieu, Emmanuel | es_ES |
dc.contributor.author | Bruland, Øyvind S. | es_ES |
dc.contributor.author | Menéndez, Pablo | es_ES |
dc.contributor.author | Inderberg, Else Marit | es_ES |
dc.contributor.author | Wälchli, Sébastien | es_ES |
dc.date.accessioned | 2023-10-23T07:18:28Z | - |
dc.date.available | 2023-10-23T07:18:28Z | - |
dc.date.issued | 2023-06-08 | - |
dc.identifier.citation | Nature Communications 14: 3375 (2023) | es_ES |
dc.identifier.uri | http://hdl.handle.net/10261/337533 | - |
dc.description.abstract | Osteosarcoma (OS) remains a dismal malignancy in children and young adults, with poor outcome for metastatic and recurrent disease. Immunotherapies in OS are not as promising as in some other cancer types due to intra-tumor heterogeneity and considerable off-target expression of the potentially targetable proteins. Here we show that chimeric antigen receptor (CAR) T cells could successfully target an isoform of alkaline phosphatase, ALPL-1, which is highly and specifically expressed in primary and metastatic OS. The target recognition element of the second-generation CAR construct is based on two antibodies, previously shown to react against OS. T cells transduced with these CAR constructs mediate efficient and effective cytotoxicity against ALPL-positive cells in in vitro settings and in state-of-the-art in vivo orthotopic models of primary and metastatic OS, without unexpected toxicities against hematopoietic stem cells or healthy tissues. In summary, CAR-T cells targeting ALPL-1 show efficiency and specificity in treating OS in preclinical models, paving the path for clinical translation. | es_ES |
dc.description.sponsorship | This study was supported by the Norwegian Research Council (Grant numbers: 284983 and 316407 to S.W. and 326811 to E.M.I), the Norwegian Health Region South East (Grant numbers: 2020601, 2018579, 2016006 and 2019062 to S.W. and 2019004 to E.M.I.) and S.J. is supported by the Norwegian Research Council under the frame of the Era-Net EURONANOMED-3 European Research project “NAN-4-TUM”. We thank Nova Southeastern University Center for Collaborative Research Core Facilities personnel Dr. Robin Krueger, Solly-Ann Barton-Case and Dr. Bojie Dai for their support in generation of RNAseq data. A.-M.G. was supported by the Swedish Society for Medical Research (SSMF). Research in P.M.’s Laboratory was funded by “la Caixa” Foundation Validate Program, ISCIII-RICORS within the Next Generation EU program (plan de recuperación, transformación y resilencia), and core support from CERCA/Generalitat de Catalunya and Fundació Josep Carreras-Obra Social la Caixa, the CaixaImpulse Grant CI21-00189, which has received funding from the European Institute of Innovation and Technology (EIT). This body of the European Union receives support from the European Union’s Horizon 2021 research and innovation program. C.P. is supported by a PFIS fellowship from Instituto de Salud Carlos III (ISCIII) (FI21/00161). | es_ES |
dc.format | application/pdf | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Springer Nature | es_ES |
dc.relation.isversionof | Publisher's version | es_ES |
dc.relation.isbasedon | Mensali, Nadia; Köksal, Hakan; Joaquina, Sandy; Wernhoff, Patrik; Casey, Nicholas P.; Romecin, Paola; Panisello, Carla; Rodriguez, René; Vimeux, Lene; Juzeniene, Asta; Myhre, Marit R.; Fåne, Anne; Castilla, Carolina; Maggadottir, Solrun Melkorka; Duru, Adil Doganay; Georgoudaki, Anna-Maria; Grad, Iwona; Maturana, Andrés Daniel; Gaudernack, Gustav; Kvalheim, Gunnar; Carcaboso, Ángel M.; Álava, Enrique de; Donnadieu, Emmanuel; Bruland, Øyvind S.; Menéndez, Pablo; Inderberg, Else Marit; Wälchli, Sébastien; 2023; Supplementary information. ALPL-1 is a target for chimeric antigen receptor therapy in osteosarcoma [Dataset]; Springer Nature; https://doi.org/10.1038/s41467-023-39097-x | es_ES |
dc.relation.isbasedon | The underlying dataset has been published as supplementary material of the article in the publisher platform at https://doi.org/10.1038/s41467-023-39097-x | es_ES |
dc.rights | openAccess | es_ES |
dc.title | ALPL-1 is a target for chimeric antigen receptor therapy in osteosarcoma | es_ES |
dc.type | artículo | es_ES |
dc.identifier.doi | 10.1038/s41467-023-39097-x | - |
dc.description.peerreviewed | Peer reviewed | es_ES |
dc.relation.publisherversion | https://doi.org/10.1038/s41467-023-39097-x | es_ES |
dc.identifier.e-issn | 2041-1723 | - |
dc.rights.license | http://creativecommons.org/licenses/by/4.0/ | es_ES |
dc.contributor.funder | Norwegian Research Council | es_ES |
dc.contributor.funder | Southern and Eastern Norway Regional Health Authority | es_ES |
dc.contributor.funder | Nova Southeastern University | es_ES |
dc.contributor.funder | Swedish Society for Medical Research | es_ES |
dc.contributor.funder | Fundación la Caixa | es_ES |
dc.contributor.funder | European Commission | es_ES |
dc.contributor.funder | Instituto de Salud Carlos III | es_ES |
dc.contributor.funder | European Institute of Innovation and Technology | es_ES |
dc.contributor.funder | Josep Carreras Leukemia Foundation | es_ES |
dc.contributor.funder | Centres de Recerca de Catalunya | es_ES |
dc.contributor.funder | Generalitat de Catalunya | es_ES |
dc.relation.csic | Sí | es_ES |
oprm.item.hasRevision | no ko 0 false | * |
dc.identifier.funder | http://dx.doi.org/10.13039/501100003748 | es_ES |
dc.identifier.funder | http://dx.doi.org/10.13039/501100002809 | es_ES |
dc.identifier.funder | http://dx.doi.org/10.13039/501100004587 | es_ES |
dc.identifier.funder | http://dx.doi.org/10.13039/501100005677 | es_ES |
dc.identifier.funder | http://dx.doi.org/10.13039/501100005416 | es_ES |
dc.identifier.funder | http://dx.doi.org/10.13039/501100000780 | es_ES |
dc.identifier.funder | http://dx.doi.org/10.13039/501100000811 | es_ES |
dc.identifier.pmid | 37291203 | - |
dc.identifier.scopus | 2-s2.0-85161398175 | - |
dc.identifier.url | https://api.elsevier.com/content/abstract/scopus_id/85161398175 | - |
dc.type.coar | http://purl.org/coar/resource_type/c_6501 | es_ES |
item.cerifentitytype | Publications | - |
item.grantfulltext | open | - |
item.openairetype | artículo | - |
item.fulltext | With Fulltext | - |
item.languageiso639-1 | en | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
Aparece en las colecciones: | (IBIS) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
osteosarcoma.pdf | 2,76 MB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
3
checked on 01-may-2024
SCOPUSTM
Citations
8
checked on 06-may-2024
WEB OF SCIENCETM
Citations
3
checked on 27-feb-2024
Page view(s)
39
checked on 07-may-2024
Download(s)
20
checked on 07-may-2024